Analysis of Novel Anticoagulants for Atrial Fibrillation – Pharmacokinetics and Pharmacological Considerations.
Artículo
en Inglés
| IMSEAR
| ID: sea-162168
ABSTRACT
Atrial Fibrillation (AF) is the most common arrhythmia. AF is a major risk factor for stoke. Warfarin has been available for more than 60 years and until recently it was the only oral anticoagulant used for the prevention of stroke. Despite the extensive studies and proven efficacy, its utility is limited by multiple factors. Warfarin interacts with a multitude of drugs and foods, has a delayed onset of action, has a narrow therapeutic range, requires routine lab monitoring and exhibits variable responses in patients. The novel agents dabigatran, rivaroxaban and apixaban have the potential to have some of the limitations of warfarin. This article will discuss the pharmacokinetic and pharmacological considerations and different characteristics of the novel anticoagulants when used for the prevention of AF.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Pirazoles
/
Piridonas
/
Fibrilación Atrial
/
Tiofenos
/
Warfarina
/
Bencimidazoles
/
Anciano de 80 o más Años
/
Anciano
/
Humanos
/
Antitrombinas
Tipo de estudio:
Factores de riesgo
Límite:
Aged80
Idioma:
Inglés
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS